Literature DB >> 11752711

Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor.

Christopher J Cohen1, Zhi Quan Xiang2, Guang-Ping Gao3, Hildegund C J Ertl2, James M Wilson3,2, Jeffrey M Bergelson1.   

Abstract

A replication-defective form of chimpanzee adenovirus type 68 (C68) has been developed to circumvent problems posed by widespread preexisting immunity to common human adenovirus vectors. To investigate the determinants of C68 tropism, its interaction with the coxsackievirus and adenovirus receptor (CAR) was studied. Although CHO cells were resistant to transduction by C68 as well as by adenovirus type 5 (Ad5), CHO cells expressing either human or murine CAR were transduced readily. C68 transduction, like Ad5 transduction, was blocked when cells were exposed to anti-CAR antibody or when virus was exposed to a soluble form of the CAR extracellular domain. These results indicate that gene delivery by C68 occurs by a CAR-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752711     DOI: 10.1099/0022-1317-83-1-151

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  29 in total

1.  Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.

Authors:  Ritu R Bradley; Diana M Lynch; Mark J Iampietro; Erica N Borducchi; Dan H Barouch
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.

Authors:  M Jeyanathan; N Thanthrige-Don; S Afkhami; R Lai; D Damjanovic; A Zganiacz; X Feng; X-D Yao; K L Rosenthal; M Fe Medina; J Gauldie; H C Ertl; Z Xing
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

Review 3.  Adenovirus receptors.

Authors:  Yuanming Zhang; Jeffrey M Bergelson
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection.

Authors:  Xiang Wang; Ping Zhou; Mangteng Wu; Kaiyan Yang; Jingao Guo; Xuchen Wang; Jun Li; Zihao Fang; Guiqin Wang; Man Xing; Dongming Zhou
Journal:  NPJ Vaccines       Date:  2020-07-09       Impact factor: 7.344

5.  A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.

Authors:  Jairo A Fonseca; Jessica N McCaffery; Elena Kashentseva; Balwan Singh; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  Vaccine       Date:  2017-05-05       Impact factor: 3.641

6.  Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors.

Authors:  Sampa Santra; Yue Sun; Birgit Korioth-Schmitz; Julie Fitzgerald; Cherie Charbonneau; Giannina Santos; Michael S Seaman; Sarah J Ratcliffe; David C Montefiori; Gary J Nabel; Hildegund C J Ertl; Norman L Letvin
Journal:  Vaccine       Date:  2009-08-04       Impact factor: 3.641

7.  A zebrafish coxsackievirus and adenovirus receptor homologue interacts with coxsackie B virus and adenovirus.

Authors:  JenniElizabeth Petrella; Christopher J Cohen; Jedidiah Gaetz; Jeffrey M Bergelson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.

Authors:  Z Q Xiang; G P Gao; A Reyes-Sandoval; Y Li; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 9.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

Review 10.  Adenovirus receptors and their implications in gene delivery.

Authors:  Anurag Sharma; Xiaoxin Li; Dinesh S Bangari; Suresh K Mittal
Journal:  Virus Res       Date:  2009-02-26       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.